Previous close | 2.2000 |
Open | 2.2000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.2000 - 2.2000 |
52-week range | 2.1300 - 3.3700 |
Volume | |
Avg. volume | 222 |
Market cap | 205.445M |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MARSEILLE, France, May 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
MARSEILLE, France, May 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2024.
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update